Differential outcomes in 3 types of acute antibody-mediated rejection

Clinical Transplantation

Volumn 23, Issue 6, 2009, Pages 951-957

  Rafiq, Muhammad A ^a,b   de Boccardo, Graciela ^a,b   Schröppel, Bernd ^a,b   Bromberg, Jonathan S ^b   Sehgal, Vinita ^a,b   Dinavahi, Rajani ^a,b   Murphy, Barbara ^a,b   Akalin, Enver ^a,b  

^a Renal Division   (United States)

^b Recanati/Miller Transplantation Institute   (United States)

Author keywords

Anti HLA antibodies; Antibody mediated rejection; Intravenous immunoglobulin; Kidney transplantation; Luminex flow beads

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; ALLOANTIBODY; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BK VIRUS; CARDIOVASCULAR DISEASE; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOMEGALOVIRUS INFECTION; DESENSITIZATION; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GLOMERULOPATHY; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLASMAPHERESIS; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; SEPSIS; T LYMPHOCYTE; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIREMIA; BIOPSY; BLOOD; COMPARATIVE STUDY; CROSS REACTION; DISEASE COURSE; GRAFT REJECTION; IMMUNOLOGY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TIME;

ADULT; AGED; BIOPSY; CROSS REACTIONS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 71149113852     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01036.x     Document Type: Article

References (36)

1. Akalin E, Watschinger B. Antibody-mediated rejection. Semin Nephrol 2007, 27:393.
2. Bray RA, Nickerson PW, Kerman RH, Gebel HM. Evolution of HLA antibody detection: technology emulating biology. Immunol Res 2004, 29:41.
3. Feucht HE. Complement C4d in graft capillaries - the missing link in the recognition of humoral alloreactivity. Am J Transplant 2003, 3:646.
4. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004, 8:535.
5. Schweitzer EJ, Wilson JS, Fernandez-Vina M. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000, 70:1531.
6. Stegall MD, Dean PG, Gloor JM. ABO-incompatible kidney transplantation. Transplantation 2004, 78:635.
7. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006, 6:346.
8. Vo AA, Toyoda M, Peng A, Bunnapradist S, Lukovsky M, Jordan SC. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 2006, 6:2384.
9. Racusen LC, Colvin RB, Solez K. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003, 3:708.
10. Lefaucheur C, Nochy D, Hill GS. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007, 7:832.
11. Gloor JM, DeGoey SR, Pineda AA. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003, 3:1017.
12. Jordan SC, Vo A, Bunnapradist S. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003, 76:631.
13. Akalin E, Ames S, Sehgal V. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation 2003, 76:1444.
14. Akalin E, Ames S, Sehgal V. Intravenous immunoglobulin and thymoglobulin induction treatment in immunologically high-risk kidney transplant recipients. Transplantation 2005, 79:742.
15. Akalin E, Bromberg JS. Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients. Hum Immunol 2005, 66:359.
16. Locke JE, Zachary AA, Haas M. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007, 7:842.
17. Bohmig GA, Wahrmann M, Regele H. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant 2007, 7:117.
18. White NB, Greenstein SM, Cantafio AW. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 2004, 78:772.
19. Jordan SC, Quartel AW, Czer LS. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998, 66:800.
20. Lehrich RW, Rocha PN, Reinsmoen N. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation. Hum Immunol 2005, 66:350.
21. Akalin E, Dinavahi R, Friedlander R. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 2008, 3:1160.
22. Akalin E, Dinavahi R, Dikman S. Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining. Clin J Am Soc Nephrol 2007, 2:1261.
23. Akalin E, Murphy B, Sehgal V, Ames S, Daly L, Bromberg JS. Rapid steroid withdrawal in hepatitis C virus-positive kidney transplant recipients. Clin Transplant 2004, 18:384.
24. Wyatt CM, Dikman S, Sehgal V. Chronic organizing microangiopathy in a renal transplant recipient. Nephrol Dial Transplant 2005, 20:1734.
25. Samaniego M, Mezrich J, Torrealba J. C4d-positive acute antibody-mediated rejection due to anti-HLA-DP antibody: a tale of one patient and a review of the University of Wisconsin experience. Clin Transplant 2006, 503.
26. Sumitran-Holgersson S, Wilczek HE, Holgersson J, Soderstrom K. Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 2002, 74:268.
27. Dragun D, Muller DN, Brasen JH. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005, 352:558.
28. Perrey C, Brenchley PE, Johnson RW, Martin S. An association between antibodies specific for endothelial cells and renal transplant failure. Transpl Immunol 1998, 6:101.
29. Mizutani K, Terasaki P, Hamdani E. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007, 7:1027.
30. Vaidya S. Clinical importance of anti-human leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation 2008, 85:1046.
31. Fidler ME, Gloor JM, Lager DJ. Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation. Am J Transplant 2004, 4:101.
32. Gloor JM, DeGoey S, Ploeger N. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004, 78:221.
33. Haas M, Rahman MH, Racusen LC. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant 2006, 6:1829.
34. Gloor JM, Cosio FG, Rea DJ. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006, 6:1841.
35. Anglicheau D, Loupy A, Suberbielle C. Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: a pilot study. Am J Transplant 2007, 7:1185.
36. Vo AA, Wechsler EA, Wang J. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am J Transplant 2008, 8:144.